ClinicalTrials.gg

Program

pirfenidone

Also written as “Pirfenidone”, “Pirfenidone Modified-Release Tablets” and “Deupirfenidone”.

Its studies are mostly in Idiopathic Pulmonary Fibrosis · Lung Injury · Lung Diseases, Interstitial · Pulmonary Fibrosis · COVID-19, led by 6 companies.

Furthest: phase 4, since Nov 4, 201529 company-led studies, 4 open or runningNext primary completion: Dec 30, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche120 open or runningphase 4since Nov 4, 2015Mar 24, 2004none ahead
GNI Group72 open or runningphase 3since Feb 26, 2019Nov 18, 2014Dec 30, 2026phase 3 · NCT07388680
PureTech52 open or runningphase 3since Dec 8, 2025Jan 21, 2020Nov 2029phase 3 · NCT07284602
Overseas Pharmaceuticals30 open or runningphase 1since Aug 22, 2024Aug 22, 2024none ahead
beijing-kawin-technology-share-holding-co-ltd10 open or runningphase 2since Dec 30, 2011Dec 30, 2011none ahead
grupo-medifarma-s-a-de-c-v10 open or runningphase 3since Jul 6, 2015Jul 6, 2015none ahead

Also a collaborator on its studies: clinipace-worldwide, novotech-australia-pty-limited, shanghai-genomics-inc and gni-eps-pharmaceuticals-inc-gni-group.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 13 studies since Mar 24, 2004.

  1. Mar 31, 2017Phase 2 study in Lung Diseases, InterstitialHoffmann-La Roche · NCT03099187 · 253 enrolled · Australia, Belgium, Canada and more
  2. Jun 26, 2017Phase 3 study in Idiopathic Pulmonary FibrosisHoffmann-La Roche · NCT03208933 · 60 enrolled · Russian Federation
  3. Feb 26, 20192 phase 3 studiesGNI Group · NCT03857854, NCT03856853
  4. Apr 2, 2019Phase 2 study in Radiation-induced Lung InjuryGNI Group · NCT03902509 · 126 enrolled · China
  5. Oct 10, 2019Phase 1 study in Renal InsufficiencyGNI Group · NCT04126538 · 24 enrolled · China
  6. Jan 21, 2020PureTech's first study: phase 2 study in LymphedemaNew to PureTechPureTech · NCT04243837 · 50 enrolled · United States, Australia
  7. Dec 2, 2020Phase 2 study in COVID-19PureTech · NCT04652518 · 185 enrolled · United States, Argentina, Brazil and more
  8. Feb 17, 2022Phase 3 study in PneumoconiosisGNI Group · NCT05288179 · 272 planned · China
  9. Apr 2, 2022Phase 2 study in Idiopathic Pulmonary FibrosisPureTech · NCT05321420 · 240 enrolled · United States, Argentina, Chile and more
  10. Aug 22, 2024Overseas Pharmaceuticals's first study: phase 1 study in Idiopathic Pulmonary FibrosisNew to Overseas PharmaceuticalsOverseas Pharmaceuticals · NCT06569381 · 18 enrolled · China
  11. Sep 6, 20242 phase 1 studies in Idiopathic Pulmonary FibrosisOverseas Pharmaceuticals · NCT06589921, NCT06588517
  12. Nov 17, 2025Phase 3 study in Radiation-induced Lung InjuryGNI Group · NCT07388680 · 298 planned · China
  13. Dec 8, 2025Phase 3 study in Idiopathic Pulmonary FibrosisPhase 3 reachedPureTech · NCT07284602 · 1,100 planned · United States, Canada
  14. Feb 19, 2026Phase 1 study in Pharmacokinetic AnalysisPureTech · NCT07456800 · 116 enrolled · United States

Ahead

  1. Dec 30, 2026Primary completion: phase 3 study in Radiation-induced Lung InjuryGNI Group · NCT07388680
  2. Nov 2029Primary completion: phase 3 study in Idiopathic Pulmonary FibrosisPureTech · NCT07284602

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 29 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07456800Pharmacokinetic Analysis · United States1CompletedPureTechJan 1, 2022116
NCT07284602Idiopathic Pulmonary Fibrosis · United States, Canada3RecruitingPureTechNov 20291,100
NCT07388680Radiation-induced Lung Injury · China3RecruitingGNI GroupDec 30, 2026298
NCT06589921Idiopathic Pulmonary Fibrosis · China1CompletedOverseas PharmaceuticalsSep 5, 202324
NCT06588517Idiopathic Pulmonary Fibrosis · China1CompletedOverseas PharmaceuticalsApr 19, 202412
NCT06569381Idiopathic Pulmonary Fibrosis · China1CompletedOverseas PharmaceuticalsOct 1, 202418
NCT05321420Idiopathic Pulmonary Fibrosis · United States, Argentina, Chile and more2Active, not recruitingPureTechOct 15, 2024240
NCT05288179Pneumoconiosis · China3RecruitingGNI GroupSep 30, 2026272
NCT04652518COVID-19 · United States, Argentina, Brazil and more2TerminatedPureTechJun 28, 2022185
NCT04243837Lymphedema · United States, Australia2TerminatedPureTechSep 9, 202250
NCT04126538Renal Insufficiency · China1UNKNOWNGNI GroupNov 25, 202124
NCT03902509Radiation-induced Lung Injury · China2CompletedGNI GroupDec 4, 2023126
NCT03857854Dermatomyositis Interstitial Lung Disease (Dm-ILD) · China3UNKNOWNGNI GroupFeb 2021152
NCT03856853Systemic Sclerosis-associated Interstitial Lung Disease (Ssc-ild) · China3UNKNOWNGNI GroupFeb 10, 2021144
NCT03208933Idiopathic Pulmonary Fibrosis · Russian Federation3CompletedHoffmann-La RocheNov 13, 201960
NCT03099187Lung Diseases, Interstitial · Australia, Belgium, Canada and more2CompletedHoffmann-La RocheNov 21, 2018253
NCT02648048Idiopathic Pulmonary Fibrosis · United States, Germany1CompletedHoffmann-La RocheNov 30, 201621
NCT02598193Idiopathic Pulmonary Fibrosis · United States, Canada, Denmark and more4CompletedHoffmann-La RocheMay 16, 201789
NCT02525484Healthy Volunteer · United States1CompletedHoffmann-La RocheAug 201544
NCT02496182Alveolitis, Extrinsic Allergic · Mexico3UNKNOWNgrupo-medifarma-s-a-de-c-vJan 201660
NCT02296281Radiation Pneumonitis2UNKNOWNGNI GroupJun 201648
NCT01933334Scleroderma, Systemic · United States, Canada, Italy2CompletedHoffmann-La RocheSep 201463
NCT01872689Idiopathic Pulmonary Fibrosis · United States, Australia, Belgium and more2CompletedHoffmann-La RocheJul 28, 2017505
NCT01504334Idiopathic Pulmonary Fibrosis · China2UNKNOWNbeijing-kawin-technology-share-holding-co-ltdNov 201280
NCT01366209Idiopathic Pulmonary Fibrosis · United States3CompletedHoffmann-La RocheFeb 2014555
NCT00662038Idiopathic Pulmonary Fibrosis · United States3CompletedHoffmann-La RocheFeb 20161,058
NCT00287729Idiopathic Pulmonary Fibrosis · United States3CompletedHoffmann-La RocheNov 2008344
NCT00287716Idiopathic Pulmonary Fibrosis · United States3CompletedHoffmann-La RocheNov 10, 2008435
NCT00080223Idiopathic Pulmonary Fibrosis · United States2CompletedHoffmann-La RocheApr 30, 201583

How it is read

Names in the registry

  • “Pirfenidone”, 26 entries
  • “Pirfenidone Modified-Release Tablets”, 4 entries
  • “Deupirfenidone”, 3 entries
  • “pirfenidone capsule”, 2 entries
  • “pirfenidone”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.